IDM Pharma, Inc. announced the completion of patient enrolment in two phase II clinical trials of Uvidem, IDM's therapeutic product for the treatment of melanoma being developed in collaboration with sanofi-aventis. Thirty-eight patients with malignant melanoma were included in the US study and 53 patients with resected stage II/III melanoma were included in the European study.

"This is another in a series of important milestone achievements we have made in the company's development programs," said Bonnie Mills, PhD, VP, Clinical Operations and General Manager US Operations for IDM. "We thank the patients, physicians and their teams whose support and enthusiasm made this possible. We anticipate that we will be able to complete the analysis of these trials and provide initial results during 2007." The preliminary results of the DC-MEL-202 trial have been submitted for presentation at ASCO 2007 in Chicago.

The US clinical trial is designed to assess the safety and clinical activity of Uvidem in patients with stage III or IV melanoma with measurable lesions. Participating centres include the University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center, the MD Anderson Cancer Center, the University of Pittsburgh, the Arizona Cancer Center and Lutheran General Cancer Care Center.

The primary objective of the European trial is the evaluation of a specific immune response against tumour antigens following treatment